Roche pledges to extend commitment to the World Federation of Hemophilia Humanitarian Aid Program to 2028

The renewed commitment will provide continued preventative (prophylactic) treatment to as many as 1,000 people withhaemophilia A in locations where there is little to no access tohaemophilia treatmentProphylactic treatment aims to prevent bleeds and allow people withhaemophilia to achieve quality of life comparable to non-haemophilic individuals. Access to this is particularly restricted in developing countries, with the limited healthcare resources reserved for emergency situations and acute bleedsMore than 940 people across 30 countries have already benefited from Roche ’s donations since the start of the partnership in February 2019Basel, 10 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has extended its commitment to the World Federation of Hemophilia (WFH) Humanitarian Aid Program until the end of 2028. Roche’s prophylactic treatment will be provided to the WFH Humanitarian Aid Program to continue to treat as many as 1,000 people with haemophilia A in locations where there is little to no access to treatment. The partnership, which was originally formed by Roche and the WFH in February 2019, marked the first time that patients in developing countries had received access to a prophylactic treatment. The donated treatment has since benefited more than 940 people across 30 countries.“Our renewed commitment will allow us to continue to help people with haemophilia A most in need,” said Bill Anderson, CEO Roche Pharmaceuticals. “We are proud...
Source: Roche Media News - Category: Pharmaceuticals Source Type: news